Table 3.
Baseline characteristics of included patients at the time of initiation of chronic dialysis
| Covariate | Overall |
|---|---|
| n | 1361 |
| Age, years | 65 (15) |
| Haemodialysis (%) | 846 (62) |
| Peritoneal dialysis (%) | 515 (38) |
| Women (%) | 553 (41) |
| BMI, kg/m2 | 26.4 (23.5, 30.3) |
| Year of dialysis start (%) | |
| 2012–13 | 425 (31) |
| 2014–15 | 308 (23) |
| 2016–17 | 628 (46) |
| CKD aetiology | |
| Diabetic nephropathy | 433 (32) |
| Nephrosclerosis | 232 (17) |
| Glomerulonephritis | 180 (13) |
| Pyelonephritis | 31 (2) |
| Polycystic kidney disease | 120 (9) |
| Other | 239 (18) |
| Unknown | 126 (9) |
| Comorbidities, n (%) | |
| Diabetes mellitus | 667 (49) |
| Hypertension | 1262 (93) |
| Myocardial infarction | 261 (19) |
| Heart failure | 369 (27) |
| Cerebrovascular disease | 224 (16) |
| Peripheral vascular disease | 227 (17) |
| Atrial fibrillation | 203 (15) |
| Stroke | 147 (11) |
| Medications, n (%) | |
| ESA | 1256 (92) |
| Iron | 919 (68) |
| ACEIs and ARBs | 933 (69) |
| β-blockers | 1041 (76) |
| Calcium channel blockers | 1099 (81) |
| Statin | 805 (59) |
| Phosphate binders | 1134 (83) |
| Sodium bicarbonate | 1042 (77) |
| Characteristics of their pre-ESKD period | |
| ERI from all pre-ESKD visits, IU/kg/week/g/dL | 0.5 (0.4–0.8) |
| Slope of eGFR decline, mL/min/1.73 m2/year | −4.0 (0.2) |
| Days observed during pre-ESKD | 463 (264–788) |
Data are presented as mean (SD), median (IQR) or counts (proportion), as appropriate.
ACEIs and ARBs, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.